Telix Pharmaceuticals reports $247 million quarterly revenue

• Telix Pharmaceuticals reported $247 million in second-quarter group revenue to mark a 21% year-over-year increase.
• The company increased research expenditure guidance and maintained tracking toward exceeding $1 billion in annual revenue.
• The financial growth follows an expanded global manufacturing network and a new strategic collaboration with Regeneron.

Telix Pharmaceuticals (NASDAQ:TLX) reported second-quarter group revenue of $247 million, representing a 21% year-over-year increase.

The precision medicine division delivered $202 million during the period, offsetting a 6% manufacturing segment decline.

The company stated it expects full-year revenue and other income to exceed $1 billion following operational growth.

The financial outlook includes $40 million in non-refundable income from a strategic collaboration with Regeneron (NASDAQ:REGN).

Management also increased the annual research and development expenditure guidance to a range of $230–$270 million.

The corporate update follows an expanded global manufacturing network and a $600 million convertible bond refinancing.